Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-20 |
2024-03 |
-0.1 |
-0.08 |
0.02 |
20.00% |
2024-03-05 |
2023-12 |
0.1 |
0.11 |
0.01 |
10.00% |
2023-11-07 |
2023-09 |
-0.09 |
-0.11 |
-0.02 |
-22.22% |
2023-08-07 |
2023-06 |
-0.13 |
-0.11 |
0.02 |
15.38% |
2023-05-15 |
2023-03 |
-0.12 |
-0.11 |
0.01 |
8.33% |
2023-02-27 |
2022-12 |
-0.14 |
-0.04 |
0.1 |
71.43% |
Date |
Firm |
Action |
From |
To |
2023-08-22 |
Truist Securities |
Upgrade |
Buy |
Buy |
2023-08-06 |
EF Hutton |
Upgrade |
Buy |
Buy |
2023-06-05 |
EF Hutton |
Upgrade |
|
Buy |
2023-05-25 |
EF Hutton |
Upgrade |
Buy |
Buy |
2023-05-23 |
EF Hutton |
Upgrade |
Buy |
Buy |
2023-05-15 |
Oppenheimer |
Upgrade |
Outperform |
Outperform |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Taylor Frigon Capital Management LLC |
1.99M |
2.27M |
2.26% |
2023-06-29 |
Rock Springs Capital Management, LP |
1.29M |
1.47M |
1.46% |
2023-06-29 |
Sphera Funds Management Ltd. |
1.23M |
1.40M |
1.39% |
2023-06-29 |
Renaissance Technologies, LLC |
1.04M |
1.18M |
1.18% |
2023-06-29 |
Macquarie Group Limited |
852.94K |
972.35K |
0.97% |
2023-06-29 |
Antonetti Capital Management Llc |
775.08K |
883.59K |
0.88% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Delaware Group Equity Fds IV-Delaware Healthcare Fund |
852.94K |
972.35K |
0.97% |
2023-08-30 |
PFS Funds-Taylor Frigon Core Growth Fund |
416.19K |
474.45K |
0.47% |
2023-07-30 |
DFA Continental Small Company Series |
113.94K |
132.17K |
0.13% |
2023-08-30 |
SPDR Portfolio Developed World ex-US ETF |
94.65K |
107.90K |
0.11% |
2023-07-30 |
DFA International Core Equity Portfolio |
58.91K |
68.33K |
0.07% |
2023-08-30 |
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF |
60.48K |
68.94K |
0.07% |